Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
December 16, 2025

Cenobamate / ontozry for treating focal onset seizures in epilepsy as of May 2025

MARA Rating Company December 16, 2025

Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma as of August 2021

MARA Rating Company December 16, 2025

Cipaglucosidase alfa / pombiliti for treating late-onset Pompe disease as of August 2023

MARA Rating Company December 16, 2025

Mavenclad / cladribine for treating relapsing-remitting multiple sclerosis as of May 2024

MARA Rating Company December 16, 2025

Mavenclad / cladribine for treating active relapsing forms of multiple sclerosis as of April 2025

MARA Rating Company December 16, 2025

Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer as of December 2024

MARA Rating Company December 16, 2025

Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over as of November 2024

MARA Rating Company December 16, 2025

Pradaxa / dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation as of July 2021

MARA Rating Company December 16, 2025

Dabrafenib / trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer as of June 2023

MARA Rating Company December 16, 2025

Olumiant / baricitinib for treating severe alopecia areata as of October 2023

MARA Rating Company December 16, 2025